LOGIN  |  REGISTER

Milestone Pharmaceuticals (NASDAQ: MIST) Stock Quote

Last Trade: US$1.79 -0.01 -0.56
Volume: 454,421
5-Day Change: 19.33%
YTD Change: 7.19%
Market Cap: US$96.570M

Latest News From Milestone Pharmaceuticals

MONTREAL and CHARLOTTE, N.C., March 28, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for etripamil, the Company’s lead investigational product for the management of... Read More
On track to resubmit NDA for etripamil in PSVT early 2Q 2024 Recent financing extends cash runway into 2026 FDA reiterated prior guidance on regulatory pathway for AFib-RVR, End of Phase 2 Meeting expected mid-2024 MONTREAL and CHARLOTTE, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the fourth quarter and year ended December 31, 2023 and provided... Read More
MONTREAL and CHARLOTTE, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will participate in a corporate panel discussion at the TD Cowen 44 th Annual Health Care Conference on March 5, 2024, at 10:30am ET. The webcast is available to watch both live and replay for approximately 90 days following the presentation in the News & Events... Read More
MONTREAL and CHARLOTTE, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the pricing of its previously announced underwritten public offering (the “Offering”) of (i) 16,666,667 of its common shares (the “Shares”) at a public offering price... Read More
MONTREAL and CHARLOTTE, N.C., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it has commenced an underwritten public offering (the “Offering”) of its common shares (the “Shares,”), and, in lieu of common shares to certain investors that so... Read More
Resubmission of NDA expected 2Q2024 Operating Runway Extended Into Mid-2025 with Cash Conservation Measures MONTREAL and CHARLOTTE, N.C., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced plans to resubmit the New Drug Application (NDA) for etripamil to the U.S. Food and Drug Administration (FDA) for paroxysmal supraventricular tachycardia (PSVT). Following the previously... Read More
MONTREAL and CHARLOTTE, N.C., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) announced today that the Company received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for self-administered etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT). Upon preliminary review, the FDA determined... Read More
MONTREAL and CHARLOTTE, N.C. , Nov. 21, 2023 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will participate in a fireside chat at the Piper Sandler 35 th Annual Healthcare Conference on Tuesday, November 28, 2023 , at 10:30 a.m. Eastern Time . The fireside chat is available to watch both live and replay for approximately 90 days following the presentation in the... Read More
New Drug Application submitted to the U.S. Food and Drug Administration for CARDAMYST ™ , the conditionally approved brand name for etripamil nasal spray, for patients with PSVT Positive Phase 2 data evaluating etripamil in AFib-RVR were a Featured Science Presentation at 2023 AHA Scientific Sessions; Phase 3 program expected to begin enrollment in mid-2024 Company to host Investor and Analyst Webcast to review data from... Read More
HealthStocksHub
Etripamil, an investigational drug, showed statistically significant reduction in ventricular rate by 30 beats per minute for episodes of atrial fibrillation with rapid ventricular rate (p < 0.0001) compared to placebo Results also showed statistically significant rapid and sustained reductions in ventricular rate and... Read More
Cardiac Electrophysiology Key Opinion Leaders joining the webcast include A. John Camm , MD, and Sean Pokorney , MD Conference call and webcast on Monday, November 13, 2023 at 8:00 a.m. ET MONTREAL and CHARLOTTE, N.C. , Nov. 7, 2023 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that the Company will host a virtual investor and analyst webcast on Monday, November 13, 2023 at 8:00 a.m. ET . The webcast... Read More
Submission seeks approval for treatment of an abnormal heart rhythm, Paroxysmal Supraventricular Tachycardia or PSVT Comprehensive data package includes positive results from pivotal Phase 3 RAPID trial which Company believes demonstrates new calcium channel blocker, etripamil, is twice as effective and three times as fast as a placebo in restoring normal heart rhythm for patients suffering from PSVT CARDAMYST ™ , the... Read More
MONTREAL and CHARLOTTE, N.C. , Oct. 6, 2023 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the "Company" or "Milestone"), today announced that the Company granted equity awards, in the form of a total of 122,000 options (the "Options") to purchase the Company's common shares, pursuant to the Company's 2021 Inducement Plan (the "Plan"), previously approved by the Company's Compensation Committee and the Board of... Read More
MONTREAL and CHARLOTTE, N.C. , Sept. 27, 2023 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that results from a double-blind, randomized, placebo-controlled Phase 2 etripamil study will be presented at the American Heart Association (AHA) Scientific Sessions 2023. Selected for a Featured Science Presentation, the ReVeRA study evaluated etripamil in emergency department patients with atrial... Read More
MONTREAL and CHARLOTTE, N.C. , Sept. 5, 2023 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of its management team will participate in a fireside chat at the H.C. Wainwright 25 th Annual Global Investment Conference on Tuesday, September 12, 2023 at 9:00 a.m. ET . A live... Read More
NDA submission for etripamil in patients with PSVT expected in October 2023 Data featured during oral session at Heart Rhythm 2023 Annual Meeting support the potential of etripamil in patients with AFib-RVR Enrollment complete in Phase 2 ReVeRA study of etripamil in patients with AFib-RVR; topline data expected in fourth quarter of 2023 MONTREAL and CHARLOTTE, N.C. , Aug. 10, 2023 /CNW/ -- Milestone Pharmaceuticals Inc.... Read More
Primary endpoint met, with 64.3% of patients who self-administered etripamil converting from supraventricular tachycardia to sinus rhythm within 30 minutes compared to 31.2% on placebo (HR = 2.62, p<0.001) Significant improvement in multiple symptoms of supraventricular tachycardia in patients receiving etripamil compared to placebo Safety and tolerability profile of repeat-dose regimen consistent with previously studied... Read More
MONTREAL and CHARLOTTE, N.C. , June 1, 2023 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of its management team will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 8:30 a.m. ET . A live webcast of the fireside chat can be... Read More
Self-administration of etripamil in patients experiencing AFib-RVR episodes resulted in a substantial reduction in ventricular rate which was sustained over 60 minutes Data featured in an oral session at the Heart Rhythm 2023 Annual Meeting Company to host virtual KOL conference call and webcast to discuss etripamil development for the treatment of AFib-RVR today at 8:00 a.m. ET MONTREAL and CHARLOTTE, N.C. , May 22, 2023... Read More
NDA submission for etripamil in patients with PSVT currently on track for 3Q23 Company to host virtual KOL event focused on etripamil for the potential treatment of AFib-RVR on Monday, May 22, 2023 Topline data from Phase 2 ReVeRA study evaluating etripamil in patients with AFib-RVR expected in 2H, 2023 Cash resources as of March 31, 2023 , together with strategic March 2023 financing, expected to fund operations into... Read More
Cardiac Electrophysiology Key Opinions Leaders to include Paul Dorian , MD, and Jonathan Piccini , MD Conference call and webcast on Monday, May 22, 2023 at 8:00 a.m. ET MONTREAL and CHARLOTTE, N.C. , May 8, 2023 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that the Company will host... Read More
MONTREAL and CHARLOTTE, N.C. , April 12, 2023 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of its management team will present at the 22 nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19, 2023 at 3:45 p.m. ET . A live webcast of the presentation can... Read More
Year-end cash resources, together with $125 million proceeds from March 2023 strategic financing, expected to fund operations into mid-2025 NDA submission for etripamil in patients with PSVT expected for 3Q23 MONTREAL and CHARLOTTE, N.C. , March 29, 2023 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines,... Read More
Proceeds from strategic financing together with year-end cash resources expected to fund operations into mid-2025 including etripamil NDA submission and launch in PSVT The combination of etripamil's strong clinical results with this strategic financing lays the foundation to deliver a therapy that empowers patients to treat supraventricular tachycardia attacks outside the emergency department MONTREAL and CHARLOTTE, N.C. ,... Read More
Both the NODE-303 and RAPID-extension studies are complete Following FDA feedback, Etripamil NDA is on-track for submission in the third quarter of 2023 Potential to be the first fast-acting, patient administered treatment to break PSVT episodes if approved MONTREAL and CHARLOTTE, N.C. , March 6, 2023 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and... Read More
MONTREAL and CHARLOTTE, N.C. , Feb. 28, 2023 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of its management team will present at the following investor conferences: The Cowen 43 rd Annual Health Care Conference on Tuesday, March 7 at 1:30 p.m. ET . The Oppenheimer 33 rd... Read More
Conference call and webcast on Tuesday, December 6, 2022 at 1:00 p.m. ET MONTREAL and CHARLOTTE, N.C. , Nov. 29, 2022 /CNW/ -- M ilestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of the Company's management team will host a virtual commercial deep-dive event on Tuesday, December 6,... Read More
MONTREAL and CHARLOTTE, N.C. , Nov. 22, 2022 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of its management team will participate in a fireside chat at the Piper Sandler 34 th Annual Healthcare Conference on Tuesday, November 29, 2022 at 1:30 p.m. ET in New York, NY . A... Read More
Chimerix

COPYRIGHT ©2023 HEALTH STOCKS HUB